• Medientyp: E-Artikel
  • Titel: Kidney re-transplantation in a child across the barrier of persisting angiotensin II type I receptor antibodies
  • Beteiligte: Gold, Annika; Fichtner, Alexander; Choukair, Daniela; Schmitt, Claus Peter; Süsal, Caner; Dragun, Duska; Tönshoff, Burkhard
  • Erschienen: Springer Science and Business Media LLC, 2021
  • Erschienen in: Pediatric Nephrology
  • Sprache: Englisch
  • DOI: 10.1007/s00467-020-04879-8
  • ISSN: 0931-041X; 1432-198X
  • Schlagwörter: Nephrology ; Pediatrics, Perinatology and Child Health
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Approximately 20% of antibody-mediated rejection (ABMR) episodes in the absence of donor-specific antibodies against human leucocyte antigens (HLA-DSA) in pediatric and adult kidney transplant recipients are associated with, and presumably caused by, antibodies against the angiotensin type 1 receptor (AT<jats:sub>1</jats:sub>R-Ab). While the role of AT<jats:sub>1</jats:sub>R-Ab for ABMR and graft failure is increasingly recognized, there is little information available on the management of these patients for re-transplantation over the barrier of persisting AT<jats:sub>1</jats:sub>R-Ab.</jats:p></jats:sec><jats:sec><jats:title>Case</jats:title><jats:p>We report on a male patient with kidney failure in infancy due to obstructive uropathy who had lost his first kidney transplant due to AT<jats:sub>1</jats:sub>R-Ab-mediated chronic ABMR. Because this antibody persisted during 4 years of hemodialysis, for the 2nd kidney transplantation (living-related transplantation from his mother), he underwent a desensitization regimen consisting of 15 plasmapheresis sessions, infusions of intravenous immunoglobulin G and thymoglobulin, as well as pharmacological blockade of the Angiotensin II (AT II) pathway by candesartan. This intense desensitization regimen transiently decreased elevated AT<jats:sub>1</jats:sub>R-Ab titers, resulting in stable short-term kidney allograft function. The subsequent clinical course, however, was complicated by acute cellular rejection and chronic ABMR due to persistent AT<jats:sub>1</jats:sub>R-Ab and de novo HLA-DSA, which shortened allograft survival to a period of only 4 years.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This case highlights the difficulty of persistently decreasing elevated AT<jats:sub>1</jats:sub>R-Ab titers by a desensitization regimen for re-transplantation and the detrimental effect of the interplay between AT<jats:sub>1</jats:sub>R-Ab and HLA-DSA on kidney transplant survival.</jats:p></jats:sec>